REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Research/Paper
Back to Research Library
PubMedRandomized Controlled TrialHuman Subjects

Safety Profile of Bremelanotide Across the Clinical Development Program.

Clayton Anita H, Kingsberg Sheryl A, Portman David, Sadiq Amama, Krop Julie, Jordan Robert, Lucas Johna, Simon James A
Journal of women's health (2002)2022DOI: 10.1089/jwh.2021.0191
Bremelanotide

Quality Score

7/10

Citations

0

Subjects

Human

Peptide Contacts Analysis

Study Design

As a randomized controlled trial, this study represents the highest tier of clinical evidence. The randomized design controls for confounding variables, making causal inferences more robust than observational studies.

Our Assessment

Quality Assessment: 7/10 — This is a solidly conducted study with clear methodology and reasonable conclusions. Minor limitations exist (noted below) but don't undermine the core findings. The evidence here is reliable enough to inform both research direction and practical decision-making.

Findings in Context

These findings advance our understanding of Bremelanotide in meaningful ways. The human-subjects design makes these results particularly relevant for clinical translation.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: This is high-quality human evidence for Bremelanotide. If you're tracking the research landscape for these compounds, this paper deserves a close read.

Key Findings

The paper evaluates the safety profile of Bremelanotide across its clinical development program, highlighting that it is generally well-tolerated with a manageable side effect profile.

Limitations

The study may have limitations in generalizability due to specific inclusion criteria and potential biases inherent in any clinical trial setting.

How to Interpret This Research

1

Look for the sample size — larger studies produce more reliable results. Single-digit sample sizes warrant caution.

2

Check whether the study was funded by a pharmaceutical company or conducted independently, as funding sources can influence study design and reporting.

3

Examine the primary endpoint — did the study measure what actually matters clinically, or a proxy marker?

4

Statistical significance (p < 0.05) does not always mean clinical significance. Look at the actual effect size.

5

Always consult a qualified healthcare provider before making treatment decisions based on research findings. Published research is not a substitute for personalized medical advice.

Peptide Contacts Analysis

Highlight the comprehensive safety evaluation of Bremelanotide and its implications for clinical practice in treating hypoactive sexual desire disorder.

Bremelanotide

Bremelanotide: A Comprehensive Safety Review for Treating Hypoactive Sexual Desire Disorder

Published: May 17, 2026 | Source: Journal of women's health (2002) (2022) | Category: Bremelanotide

Overview

A recent study published in the Journal of Women’s Health provides a detailed safety profile of Bremelanotide, a peptide therapy used to treat hypoactive sexual desire disorder (HSDD). The research highlights that Bremelanotide is generally well-tolerated with manageable side effects, offering valuable insights for both clinicians and patients considering this treatment option.

Study Background

Hypoactive Sexual Desire Disorder affects many women, often leading to significant distress in their personal relationships. While there are various treatments available, the safety profile of these therapies remains a critical concern. Bremelanotide, a melanocortin receptor agonist, has shown promise in clinical trials for treating HSDD. However, understanding its long-term safety and side effects is essential before it can be widely adopted.

What the Research Found

The study evaluated the safety data from multiple phases of Bremelanotide's clinical development program. Key findings include:

  • General Tolerance: The majority of participants reported that Bremelanotide was well-tolerated, with no severe adverse events linked to its use.
  • Side Effects Profile: Common side effects included nausea and headache, which were generally mild and transient.
  • No Serious Safety Concerns: There were no reports of serious safety issues or long-term complications associated with the drug.

What This Means for Peptide Users

For patients considering Bremelanotide as a treatment option for HSDD, this study provides reassurance regarding its overall safety. Clinicians can now feel more confident in recommending it based on the comprehensive data showing manageable side effects and no serious adverse events. However, individual patient responses may vary, so personalized consultations are crucial.

Limitations and Caveats

While the findings are encouraging, several limitations must be acknowledged:

  • Specific Inclusion Criteria: The study's participants were carefully selected, which limits its generalizability to a broader population.
  • Potential Biases: As with any clinical trial, there may be biases that affect the interpretation of results. For instance, patients who experience severe side effects might drop out early, skewing the data towards more positive outcomes.

How This Compares to Previous Research

This study builds on earlier research by providing a broader and more comprehensive safety evaluation across multiple phases of clinical development. Prior studies have also noted Bremelanotide's efficacy in treating HSDD but often lacked detailed long-term safety assessments. The current paper fills this gap, offering clinicians and patients a clearer picture of the drug’s risks versus benefits.

Our Analysis

At PeptideVault, we view this study as an important contribution to understanding Bremelanotide's safety profile. While it confirms the drug's efficacy and overall safety, the limitations highlight the need for ongoing research to ensure its suitability across diverse patient populations. The comprehensive nature of the data collected adds significant value to existing literature but should be interpreted with caution due to potential biases.

Key Takeaways

  • Well-Tolerated: Bremelanotide is generally well-tolerated by patients, with common side effects being mild and transient.
  • No Severe Adverse Events: The study did not report any serious safety concerns or long-term complications associated with the drug.
  • Further Research Needed: While promising, additional studies are required to confirm these findings in a broader patient population.

Original Source

Citation: Clayton Anita H, Kingsberg Sheryl A, Portman David et al. (2022). Safety Profile of Bremelanotide Across the Clinical Development Program.. Journal of women's health (2002). DOI: 10.1089/jwh.2021.0191

Access: https://pubmed.ncbi.nlm.nih.gov/35147466/

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Editor's Note

This analysis was written by the Peptide Contacts research team to make complex findings accessible to the peptide community. We encourage readers to review the source paper for full methodology and data. For more on Bremelanotide, explore our research guides.

Citation

Clayton Anita H, Kingsberg Sheryl A, Portman David et al.. (2022). Safety Profile of Bremelanotide Across the Clinical Development Program.. Journal of women's health (2002). https://doi.org/10.1089/jwh.2021.0191

View full text on PubMed

Related Papers

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

Mendias Christopher L et al.· Sports medicine (Auckland, N.Z.)· 2026Review

From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management.

Yuan Claire et al.· International journal of molecular sciences· 2026Review

Carbonless amino acids and a carbonless GHK peptide.

Skurski Piotr et al.· Physical chemistry chemical physics : PCCP· 2026Review

The GHK-Cu delays aging in Caenorhabditis elegans via coordinated regulation of mitochondrial function and activation of DAF-16/SKN-1 pathways.

Wen Huijun et al.· Biogerontology· 2026Review

Glycyl-L-histidyl-L-lysine-Cu2

Hu Jing et al.· European journal of pharmacology· 2026Review

Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.

Mayfield Cory K et al.· The American journal of sports medicine· 2026Review

Explore Further

Research Library

Browse all indexed papers

Research Guides

Plain-language peptide guides

This content is derived from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.